<DOC>
	<DOCNO>NCT00963313</DOCNO>
	<brief_summary>Based publish data accord approved product label ankylose spondylitis psoriatic arthritis , expect adalimumab 40 mg every 14 day effective psoriatic arthritic patient axial involvement .</brief_summary>
	<brief_title>A 24 Week Open Label Study Utility Adalimumab Active Axial Forms Psoriatic Arthritis</brief_title>
	<detailed_description>A recent review GRAPPA group evaluate therapy PsA include peripheral axPsA . Analysing particularly result present biologic therapy prove outcome data 24 week show excellent result treatment peripheral form PsA either three biologics disposable market , say infliximab , etanercept adalimumab . However come analyse data PsA patient axPsA result . The design clinical trial evaluate axial outcome therefore possibility know whether therapy useful axPsA . This open label multicenter study design evaluate effectivity adalimumab 40 mg every 2 week 24 week patient active axial PsA despite receive Methotrexate , Sulfasalazine , Leflunomide Cyclosporine , plus NSAIDs 10 mg corticosteroid .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Males female age 18 70 year . A negative pregnancy test woman childbearing potential screening period . Subject must evaluate active latent TB ( tuberculosis ) infection use PPD skin test ( Mantoux test ) , Booster test , chest xray detail review subjetc´s medical history . Subjects doctor decide prescribe adalimumab , fulfil requirement treatment . Diagnosed PsA accord CASPAR criterion . Axial disease accord radiological criterion ( least unilateral sacroilitis grade II ) spinal inflammatory symptom . Disease duration le 24 week Patients peripheral involvement ( mixed form APs ) must take MTX least 12 week screen stable dos 10 25 mg/week 8 week screen , salazopyrine 3 mg/daily , cyclosporin 2mg/kg leflunomide 20 mg daily condition MTX . Patient 's dos NSAIDs oral corticosteroid ( ≤ 10 mg/day prednisone equivalent ) keep stable 4 week screen . Contraindications treatment antiTNF . Prior treatment TNF inhibitor investigational drug last 30 day ( etanercept 4 week , infliximab 8 week ) . Uncontrolled diabetes . Uncontrolled high blood pressure . Unstable ischemic heart disease . Congestive heart failure . Severe pulmonary disease . Chronic leg ulcer . History cancer malignant lymphoproliferative disease . Positive serology Hepatitis B indicate active infection positive serology Hepatitis C. History positive HIV status . Persistent , recurrent severe infection require hospitalization treatment oral antibiotic within 14 day prior enrollment . Previous diagnosis sign highly indicative central nervous system demyelinate disease . Active tuberculosis , histoplasmosis listeriosis . History presence confirm blood dyscrasia . Female subject pregnant breastfeeding . History clinically significant drug alcohol abuse last year . Treatment MTX , salazopyrine , ciclosporin leflunomide initiate within last 4 week screen . Treatment corticosteroid ( &gt; 10mg/day equivalent modify dose within previous 4 week screen ) . And patient intraarticular corticoid infiltration practise within last 4 week screen exclude study . Treatment one NSAID within last 4 week screen . Patients treated DMARD different MTX , cyclosporine , leflunomide sulfasalazine . Dosage concomitant MTX , cyclosporine , leflunomide sulfasalazine must stable study , otherwise properly justify recorded case report form . Patients treated analgesic different acetominophen , NSAIDs , oxycodone , codeine , propoxyphene , tramadol , hydrocodone combination product equivalent . The use potent opioids permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Axial psoriatic arthritis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
	<keyword>anti-TNF</keyword>
</DOC>